Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 30Terminated 5Withdrawn 2Unknown 2Recruiting 2Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma, Non-Hodgkin 1Hodgkin Disease 1

Interventions

Dexamethasone 98daratumumab 57Lenalidomide 53Bortezomib 38pomalidomide 37Cyclophosphamide 37carfilzomib 25Calcium Dobesilate 25fludarabine 22talquetamab 19iberdomide 18isatuximab 17Specimen Handling 17Magnetic Resonance Spectroscopy 17Biopsy 15selinexor 13dexamethasone acetate 12belantamab mafodotin 12Melphalan 12dexamethasone 21-phosphate 11auricularum 10venetoclax 8fludarabine phosphate 7elotuzumab 7X-Rays 6tocilizumab 5Blood Specimen Collection 5ruxolitinib 4ixazomib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × plerixafor × Plasma cell × Clear all
NCT06207799 2026-02-19

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Recruiting
40 enrolled
Plasma cell

Multiple Myeloma

NCT07188090 2025-11-28

HSCT

Thomas Jefferson University

Phase 2 Recruiting
100 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡